Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

ABSTRACT: In recent years, heterologous prime-boost vaccines have been demonstrated to be an effective strategy for generating protective immunity, consisting of both humoral and cell-mediated immune responses against a variety of pathogens including HIV-1. Previous reports of preclinical and clinical studies have shown the enhanced immunogenicity of viral vector or DNA vaccination followed by heterologous protein boost, compared to using either prime or boost components alone. With such approaches, the selection of an adjuvant for inclusion in the protein boost component is expected to impact the immunogenicity and safety of a vaccine. In this study, we examined in a mouse model the serum cytokine and chemokine profiles for several candidate adjuvants: QS-21, Al(OH)3, monophosphoryl lipid A (MPLA)

SUBMITTER: Buglione-Corbett R 

PROVIDER: S-EPMC3760864 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature